Our purpose is to report on a prospective study on four years' use of isoprenaline when clinically necessary and pacemaker if isoprenaline failed. This approach was chosen as we were not convinced that the routine use of the pacemaker was preferable, particularly in a hospital without university facilities, even if pacemaker therapy of chronic AV block were currently applied.
Acute myocardial infarction complicated by AV block carries a high mortality (Epstein et al., I966) . Most authors (Gregory and Grace, 1968; Kimball and Killip, I968; Sutton, Chatterjee, and Leatham, I968; Beregovich et al., I969; Grendahl and Sivertssen, I969) suggest routine use of temporary pacemaker in second or third degree AV block. Scott et al. (I967) used either isoprenaline or pacemaker and recommended pacemaker when there was congestive heart failure, shock, or syncope.
Our purpose is to report on a prospective study on four years' use of isoprenaline when clinically necessary and pacemaker if isoprenaline failed. This approach was chosen as we were not convinced that the routine use of the pacemaker was preferable, particularly in a hospital without university facilities, even if pacemaker therapy of chronic AV block were currently applied.
Patients and methods Table i shows that Io5 of i665 patients with acute myocardial infarction admitted from January I966 to March 1970 had second or third degree AV block, a mean frequency of 6-3 per cent. The increasing numbers of block are probably due to better monitoring, after a four-bed coron-ary care unit was established during I967-I968. Our medical department has 200 beds, however, and monitoring was only possible in about a third of the patients with acute infarction. Block of short duration after resuscitation may be due to metabolic acidosis (Stewart et al., 1965) and has been excluded. Otherwise, all patients were included, as well as those who died before therapy could be given. The mean age was 66 years. The time interval from the onset of pain to admission was a quarter of an hour to 4 days, on average 13 hours, and most often 6 to 8 hours. Shock (peripheral vasoconstriction, cerebral symptoms, a systolic blood pressure less than go, and oliguria) and/or congestive heart failure (pulmonary oedema) occurred in 69 patients.
An intravenous 5 per cent glucose drip was established. If heart rate fell below 50, with hypotension, shock, congestive heart failure, ventricular arrhythmias, or Adams-Stokes attacks, isoprenaline was given as well, 4 mg/l., i Fig/min.
The dose was carefully increased if necessary and varied from i to i6, usually I tO 2, and rarely more than 3 ,Ag/min. The duration of therapy was I to 14 days, usually 4 days. Isoprenaline alone was given to 47 patients. If isoprenaline failed to improve heart rate, an Elema unipolar or a Medtronic bipolar electrode was inserted transvenously under fluoroscopy to the right ventricle. An external fixed rate pacemaker was used in 6 patients, and later a QRS inhibited Medtronic pacemaker in 8. The electrodes were kept in place for three weeks in the surviving patients. Nine patients died so rapidly that there was no time for effective therapy. Conservative treatment of AV block in acute myocardial infarction 597
Eleven of them died during the first few hours, one on the 2nd and one on the 30th day, while one survived. In 7 patients AV block occurred after admission and after shock had developed. All of them died within a few hours. Of the 4 patients whose AV block occurred after ventricular fibrillation and persisted from hours to days, only i survived, 2 died from ruptured myocardium, and i from congestive heart failure. Ventricular tachycardia occurred in 7 patients, only i having block and 6 sinus rhythm. Ventricular fibrillation occurred in i6 patients (5 during the first two days, 6 others in the first week, and 5 from 2 to 4 weeks after onset of symptoms). Five had block and ii had reverted to sinus rhythm. Five of them received isoprenaline with addition of lignocaine if frequent extrasystoles were present. Only one had another attack of fibrillation which did not recur after increasing the lignocaine dose.
As seen in Table 3 , shock and/or heart 'failure were the most frequent causes of death. It is noted that 14 patients died suddenly, 6 in ventricular fibrillation and 5, with previous bundle-branch block, of asystole, while 3 patients were not monitored. Necropsy in 30 patients showed ruptured myocardium in 5.
The duration of block in the 78 patients who reverted to sinus rhythm was a few hours to 2 days in 39, 3 tO 7 days in 3I, and more than one week in 8. In 4 patients AV block recurred after 2, 2, and 8 days, and in the fourth, several times for up to 6 weeks. Three patients were discharged from hospital with total AV block. A permanent pacemaker was implanted in one while the two others using .isoprenaline sublingually were free of symp- failure after i5 to 3I days, i had a fresh infarct on the 25th day, i had ventricular fibrillation on the sth day, and 2 without monitoring died suddenly on the 6th and gth days.
Sinus rhythm was present in 7 and persisting AV block in i patient.
Isoprenaline caused an increase in heart rate/blood pressure and/or terminated further Adams-Stokes attacks in 38 patients, an increase in heart rate but only a temporary increase in blood pressure in i2, a slight rise in heart rate only in 8, and in 2 had to be terminated because of increasing ventricular extrasystoles. The average heart rate was 73, being less than 70 in only 4 patients (58, 60, 64, 64) . In 5 patients immediate conversion to sinus rhythm occurred.
Complications in the isoprenaline treated group were few. Among 8 patients with ventricular fibrillation in this group, 4 had the arrhythmia before AV block and before isoprenaline was given, and in 2 it occurred after isoprenaline had been discontinued (for 2 and 5 days). Fibrillation during isoprenaline therapy occurred in 3 patients, in 2 while the dose was rapidly increased because of falling blood pressure. One of the latter had had fibrillation before AV block. Cardioversion was successful in both, and isoprenaline drip was continued with addition of lignocaine without further complications. The third patient had shock and died in asystole after defibrillation.
The transvenous pacemaker was used because of further Adams-Stokes attacks in 3 patients, persistent hypotension, or congestive heart failure with bradycardia or alternating bradycardia/tachycardia in 8, and increase of ventricular extrasystoles during isoprenaline in 2. One was given a pacemaker without attempting isoprenaline.
Complications during pacemaker therapy
In one patient ventricular fibrillation occurred repeatedly as soon as the electrode entered the right ventricle. It was therefore placed in the right atrium and pacing was not established. On the fifth day he died of recurrent fibrillation, necropsy showing that the electrode tip had entered the right ventricle. Mechanical irritation might therefore have been the cause of death. This was the single patient who died among the I7 with inferior infarction, normal QRS, and gradual development of AV block. A second patient with a demand pacemaker was in good condition with sinus rhythm until on the eighth day she developed increasing ventricular extrasystoles, and despite treaunent with lignocaine, died of recurrent ventricular tachycardia/fibrillation. Turning the pacemaker off or increasing the rate up to 120 a minute had no effect. Electrocardiogram strips taken when ventricular tachycardia developed did not suggest interference which may also occur with a demand pacemaker by low endocardial potentials. Mechanical irritation must therefore also be kept in mind in this case. In 2 patients with fixed rate pacemaker ventricular fibrillation developed after 7 and I8 days, in the latter preceded by interference phenomena. The first patient was converted to sinus rhythm but died two hours later with asystole. The pacemaker system was intact. In one patient pacemaker failure developed after one day and the patient died rapidly in shock. The electrode was found to be defective.
The causes of death in the various treatment groups are set out in Table 4 . Ventricular fibrillation was relatively frequent in patients treated with pacemaker. From Table 5 it is apparent that the few survivors among those having bundle-branch block were approximately equally distributed between the three treatment groups. Fig. 3 shows that a large proportion of patients dying after the first 2 days had reverted to sinus rhythm, which indicates that complications other than AV block influence mortality.
Late results A second infarction occurred in 8 of the surviving patients. Temporary AV block reappeared in one, a second died with asystole without preceding AV block, and 6 patients had sinus rhythm. 
Conclusions
Advanced AV block in myocardial infarction carries a high mortality despite a treatment programme using isoprenaline in cases of circulatory symptoms and a pacemaker if isoprenaline fails. Our results did not differ from compiled reports on routine pacemaker therapy, and the high mortality may at least partly be explained by associated complications of a massive infarction, e.g. power failure and ruptured myocardium.
Analysis of the results shows that patients with inferior infarction, narrow QRS segment, and gradual development of AV block are not likely to need pacing. The value of low doses of isoprenaline in relieving symptoms such as syncope and circulatory failure has been shown. Pacemaker therapy is not without complications, e.g. mechanical irritation by the electrode. However, by analysing our causes of death and comparing our results with those of others, there appears to be scope for some improvement, e.g. by refined pacemaker technique combined with a liberal use of drugs to combat arrhythmias and congestive failure. 
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